These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 19008174)

  • 1. Low trough levels of tipranavir in a combination antiretroviral therapy of tipranavir/ritonavir and tenofovir require therapeutic drug monitoring.
    Langmann P; Winzer R; Schirmer D; Heinz W; Leyh M; Guhl C; Weissbrich B; Klinker H
    Eur J Med Res; 2008 Oct; 13(10):469-71. PubMed ID: 19008174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The benefit of simplification from tipranavir/ritonavir 500/200 bid to 500/100 bid guided by therapeutic drug monitoring.
    Morello J; Rodríguez-Novoa S; Blanco F; Vispo E; Barreiro P; Gonzalez-Pardo G; Jiménez-Nácher I; González-Lahoz J; Soriano V
    Ther Drug Monit; 2010 Apr; 32(2):242-4. PubMed ID: 20216112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of ritonavir dose reduction based on the tipranavir inhibitory quotient in HIV-infected patients on salvage antiretroviral therapy with tipranavir/ritonavir.
    Moltó J; Valle M; Santos JR; Miranda C; Cedeño S; Negredo E; Yritia M; Videla S; Clotet B
    AIDS Res Hum Retroviruses; 2010 Nov; 26(11):1191-6. PubMed ID: 20860529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic characterization of three doses of tipranavir boosted with ritonavir on highly active antiretroviral therapy in treatment-experienced HIV-1 patients.
    Goebel FD; MacGregor TR; Sabo JP; Castles M; Johnson PA; Legg D; McCallister S
    HIV Clin Trials; 2010; 11(1):28-38. PubMed ID: 20400409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compromised immunologic recovery in patients receiving tipranavir/ritonavir coadministered with tenofovir and didanosine in Randomized Evaluation of Strategic Intervention in multidrug-resiStant patients with tipranavir (RESIST) studies.
    Clotet B; Negredo E; Girard PM; Youle M; Neubacher D
    J Acquir Immune Defic Syndr; 2007 Aug; 45(4):479-81. PubMed ID: 17622838
    [No Abstract]   [Full Text] [Related]  

  • 6. Steady-state disposition of the nonpeptidic protease inhibitor tipranavir when coadministered with ritonavir.
    Chen L; Sabo JP; Philip E; Mao Y; Norris SH; MacGregor TR; Wruck JM; Garfinkel S; Castles M; Brinkman A; Valdez H
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2436-44. PubMed ID: 17485497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide.
    González de Requena D; Calcagno A; Bonora S; Ladetto L; D'Avolio A; Sciandra M; Siccardi M; Bargiacchi O; Sinicco A; Di Perri G
    AIDS; 2006 Oct; 20(15):1977-9. PubMed ID: 16988521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.
    Hicks CB; Cahn P; Cooper DA; Walmsley SL; Katlama C; Clotet B; Lazzarin A; Johnson MA; Neubacher D; Mayers D; Valdez H;
    Lancet; 2006 Aug; 368(9534):466-75. PubMed ID: 16890833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers.
    MacGregor TR; Sabo JP; Norris SH; Johnson P; Galitz L; McCallister S
    HIV Clin Trials; 2004; 5(6):371-82. PubMed ID: 15682350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tipranavir: a review of its use in the management of HIV infection.
    Orman JS; Perry CM
    Drugs; 2008; 68(10):1435-63. PubMed ID: 18578560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction therapy with enfuvirtide-based highly active antiretroviral therapy in a patient with acute HIV-1 infection.
    Polk C; Chan-Tack KM; Kopack AM; Amoroso A
    AIDS Patient Care STDS; 2007 Feb; 21(2):75-7. PubMed ID: 17328655
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients.
    Gathe JC; Pierone G; Piliero P; Arasteh K; Rubio R; Lalonde RG; Cooper D; Lazzarin A; Kohlbrenner VM; Dohnanyi C; Sabo J; Mayers D
    AIDS Res Hum Retroviruses; 2007 Feb; 23(2):216-23. PubMed ID: 17263650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.
    Bifano M; Hwang C; Oosterhuis B; Hartstra J; Grasela D; Tiessen R; Velinova-Donga M; Kandoussi H; Sevinsky H; Bertz R
    Antivir Ther; 2013; 18(7):931-40. PubMed ID: 23963204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients.
    Moltó J; Ruiz L; Valle M; Martinez-Picado J; Bonjoch A; Bravo I; Negredo E; Heilek-Sneider GM; Clotet B
    Antivir Ther; 2006; 11(1):47-51. PubMed ID: 16518959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring.
    Rodríguez-Nóvoa S; Morello J; Barreiro P; Maida I; García-Gascó P; Vispo E; González-Pardo G; Parra A; Jiménez-Nácher I; Soriano V
    AIDS Res Hum Retroviruses; 2008 Jun; 24(6):821-5. PubMed ID: 18507524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tipranavir: a novel nonpeptidic protease inhibitor of HIV.
    King JR; Acosta EP
    Clin Pharmacokinet; 2006; 45(7):665-82. PubMed ID: 16802849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies for overcoming resistance in HIV-1 infected patients receiving HAART.
    Clotet B
    AIDS Rev; 2004; 6(3):123-30. PubMed ID: 15595429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switch from enfuvirtide to raltegravir lowers plasma concentrations of darunavir and tipranavir: a pharmacokinetic substudy of the EASIER-ANRS 138 trial.
    Goldwirt L; Braun J; de Castro N; Charreau I; Barrail-Tran A; Delaugerre C; Raffi F; Lascoux-Combe C; Aboulker JP; Taburet AM; Molina JM
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3613-5. PubMed ID: 21576452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic profile in late pregnancy and cord blood concentration of tipranavir and enfuvirtide.
    Weizsaecker K; Kurowski M; Hoffmeister B; Schürmann D; Feiterna-Sperling C
    Int J STD AIDS; 2011 May; 22(5):294-5. PubMed ID: 21571982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients.
    de Mendoza C; Morelló J; Garcia-Gascó P; Rodríguez-Novoa S; Soriano V
    Expert Opin Pharmacother; 2007 Apr; 8(6):839-50. PubMed ID: 17425479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.